septemb
saudi
arabian
physician
report
isol
novel
coronaviru
patient
pneumonia
promedmail
within
day
viru
detect
qatari
patient
receiv
intens
care
london
hospit
situat
reminisc
role
air
travel
play
spread
sever
acut
respiratori
syndrom
coronaviru
sarscov
sarscov
origin
china
guangdong
provinc
affect
patient
countri
contain
month
later
year
emerg
novel
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
caus
laboratoryconfirm
case
death
emerg
second
highli
pathogen
coronaviru
within
decad
highlight
import
coordin
global
respons
incorpor
reservoir
surveil
highcontain
capac
fundament
appli
research
program
depend
commun
pathway
ensur
outbreak
contain
review
current
state
knowledg
epidemiolog
ecolog
molecular
biolog
clinic
featur
intervent
strategi
novel
coronaviru
merscov
coronavirus
famili
coronavirida
subfamili
coronavirina
circul
divers
array
mammalian
avian
reservoir
includ
human
bat
pig
cat
dog
rodent
bird
perlman
netland
coronavirus
cov
classifi
four
genera
alpha
beta
gamma
deltacoronaviru
envelop
positivestrand
rna
virus
nm
size
master
de
groot
spike
glycoprotein
radiat
viru
envelop
spheric
particl
respons
characterist
crownlik
appear
coronavirus
fig
four
coronavirus
continu
circul
human
popul
caus
gener
mild
respiratori
diseas
alphacoronaviru
betacoronaviru
hamr
procknow
mcintosh
et
al
fouchier
et
al
van
der
hoek
et
al
woo
et
al
addit
two
zoonot
introduct
coronavirus
human
popul
last
decad
associ
acut
respiratori
distress
syndrom
ard
high
case
fatal
rate
sever
acut
respiratori
syndrom
cov
sarscov
drosten
et
al
kuiken
et
al
middl
east
respiratori
syndrom
cov
merscov
zaki
et
al
sarscov
caus
first
pandem
centuri
result
c
human
case
case
fatal
rate
sar
epidemiolog
work
group
addit
impact
sarscov
infect
individu
global
public
health
commun
econom
cost
sarscov
outbreak
event
estim
billion
brahmbhatt
dutta
although
laboratoryconfirm
case
merscov
current
report
high
case
fatal
rate
travelrel
spread
across
multipl
countri
reminisc
sarscov
pandem
viru
detect
case
definit
first
human
case
merscov
identifi
use
pancoronaviru
reversetranscriptas
polymeras
chain
reaction
rtpcr
assay
zaki
et
al
mer
covspecif
quantit
rtpcr
qrtpcr
target
region
upstream
e
protein
gene
open
read
frame
rapidli
develop
becom
standard
laboratori
test
diagnosi
merscov
corman
et
al
addit
qrtpcr
target
rnadepend
rna
polymeras
rdrp
nucleocapsid
n
gene
develop
confirmatori
assay
corman
et
al
world
health
organ
case
definit
merscov
focus
patient
suffer
febril
acut
respiratori
diseas
direct
epidemiolog
link
anoth
confirm
case
resid
travel
merscovsourc
countri
confirmatori
laboratori
test
requir
posit
qrtpcr
least
two
specif
genom
target
singl
posit
target
qrtpcr
combin
sequenc
second
target
center
diseas
control
prevent
instanc
inadequ
test
neg
test
patient
direct
epidemiolog
link
confirm
merscov
case
determin
probabl
case
merscov
infect
present
acut
febril
respiratori
ill
primari
case
merscov
confin
six
countri
middl
east
saudi
arabia
unit
arab
emir
qatar
jordan
oman
kuwaittravelrel
case
identifi
tunisia
unit
kingdom
franc
germani
itali
fig
bermingham
et
al
buchholz
et
al
gulland
b
health
protect
agenc
hijawi
et
al
maill
et
al
memish
et
al
puzelli
et
al
limit
secondari
transmiss
occur
merscov
introduct
tunisia
franc
unit
kingdom
import
case
merscov
infect
germani
itali
lead
subsequ
confirm
infect
buchholz
et
al
gulland
b
health
protect
agenc
puzelli
et
al
case
merscov
occur
saudi
arabia
larg
within
riyadh
eastern
provinc
center
diseas
control
prevent
januari
confirm
case
merscov
fatal
fig
although
case
clinic
sever
contact
surveil
uncov
least
subclin
mild
infect
center
diseas
control
prevent
case
fatal
ratio
merscov
much
higher
sarscov
cfr
sar
epidemiolog
work
group
averag
age
fig
falsecolor
merscov
particl
visual
electron
microscopi
merscov
particl
yellow
attach
surfac
cell
red
characterist
merscov
spike
glycoprotein
clearli
visibl
surfac
merscov
particl
merscov
case
year
maletofemal
ratio
merscov
research
group
case
fatal
ratio
maletofemal
ratio
decreas
incid
merscov
increas
chang
may
attribut
improv
case
surveil
penttinen
et
al
interestingli
three
quarter
merscov
case
occur
patient
comorbid
merscov
research
group
common
comorbid
merscov
case
diabet
hypertens
obes
cancer
chronic
kidney
heart
lung
diseas
comorbid
like
affect
diseas
progress
outcom
strong
correl
chronic
diseas
merscov
may
bias
high
rate
risk
factor
popul
affect
countri
kingdom
saudi
arabia
instanc
preval
typeii
diabet
across
age
preval
obes
aldaghri
et
al
one
quarter
adult
male
smoke
epidemiolog
pathogenesi
studi
necessari
discern
comorbid
impact
suscept
progress
merscov
infect
clinic
manifest
merscov
rang
subclin
infect
sever
respiratori
diseas
symptomat
patient
often
present
fever
myalgia
sore
throat
short
breath
cough
occasion
hemoptysi
albarrak
et
al
assiri
et
al
drosten
et
al
guberina
et
al
gueri
et
al
health
protect
agenc
memish
et
al
c
crystal
structur
merscov
bound
receptor
determin
lu
et
al
bermingham
et
al
corman
et
al
merscov
infect
rhesu
macaqu
fullfil
koch
postul
treatment
ribavirin
improv
outcom
merscovinfect
rhesu
macaqu
phylogenet
analysi
merscov
genom
suggest
multipl
zoonot
introduct
cotten
et
al
merscov
neutral
antibodi
found
omani
camel
reusken
et
al
rna
fragment
ident
merscov
recov
egyptian
tomb
bat
saudi
arabia
memish
et
al
hospit
outbreak
merscov
saudi
arabia
form
largest
cluster
date
assiri
et
al
puzelli
et
al
gastrointestin
symptom
diarrhea
vomit
also
common
gueri
et
al
memish
et
al
although
coinfect
limit
merscov
coinfect
klebsiella
pneumonia
staphylococcu
aureu
candida
speci
influenza
viru
rhinoviru
herp
simplex
viru
report
zaki
et
al
assiri
et
al
drosten
et
al
gueri
et
al
health
protect
agenc
omrani
et
al
clinic
describ
patient
shown
abnorm
chest
radiograph
spectrum
lower
pulmonari
infiltr
consolid
consist
viral
pneumonia
albarrak
et
al
zaki
et
al
assiri
et
al
drosten
et
al
guberina
et
al
gueri
et
al
memish
et
al
first
merscov
patient
suffer
sever
diseas
requir
intens
care
mechan
ventil
extracorpor
membran
oxygen
merscov
research
group
hematolog
abnorm
report
clinic
case
includ
thrombocytopenia
lymphopenia
lymphocytosi
neutrophilia
kidney
failur
necessit
renal
replac
therapi
report
number
merscov
case
albarrak
et
al
zaki
et
al
drosten
et
al
guberina
et
al
gueri
et
al
memish
et
al
omrani
et
al
absenc
postmortem
examin
direct
evid
merscov
replic
renal
tissu
mani
case
renal
involv
explain
preexist
condit
hemorrhag
complic
organ
stress
due
extrem
hypoxemia
albarrak
et
al
drosten
et
al
gueri
et
al
longterm
sequela
acut
merscov
yet
describ
clinic
treatment
merscov
patient
center
intens
care
drug
treatment
consist
broadspectrum
antibiot
often
oseltamivir
drug
target
influenza
viru
albarrak
et
al
zaki
et
al
assiri
et
al
drosten
et
al
gueri
et
al
memish
et
al
omrani
et
al
corticosteroid
use
patient
antifung
administ
necessari
zaki
et
al
assiri
et
al
drosten
et
al
gueri
et
al
memish
et
al
omrani
et
al
patient
progress
sever
acut
respiratori
distress
provid
oxygen
therapi
mechan
ventil
extracorpor
membran
oxygen
assiri
et
al
drosten
et
al
gueri
et
al
health
protect
agenc
memish
et
al
omrani
et
al
five
clinic
describ
saudi
patient
treat
ribavirin
one
given
interferona
ifna
patient
also
infus
intraven
immunoglobulin
clinic
case
studi
analys
merscov
patient
receiv
treatment
ribavirin
immunoglobulin
publish
rapid
fullgenom
sequenc
provid
first
insight
origin
merscov
van
boheemen
et
al
cotten
et
al
phylogenet
analysi
show
close
genet
related
merscov
group
c
betacoronavirus
detect
insectivor
bat
woo
et
al
although
molecular
clock
analys
suggest
unlik
direct
ancestor
merscov
fig
lau
et
al
sinc
merscov
identif
close
relat
coronaviru
sequenc
detect
bat
africa
asia
america
eurasia
suggest
widespread
circul
merscovrel
virus
order
chiroptera
direct
contact
human
bat
limit
intermedi
speci
often
play
role
transmiss
emerg
virus
bat
human
field
et
al
luo
et
al
mahalingam
et
al
nel
anecdot
evid
merscov
patient
contact
farm
anim
report
case
albarrak
et
al
buchholz
et
al
drosten
et
al
merscov
research
group
suspicion
potenti
sourc
merscov
focus
livestock
common
arabian
peninsula
goat
sheep
dromedari
camel
cow
first
evid
exist
intermedi
anim
reservoir
detect
merscov
neutral
antibodi
dromedari
camel
oman
canari
island
spain
reusken
et
al
subsequ
studi
detect
merscov
neutral
antibodi
dromedari
camel
egypt
jordan
saudi
arabia
importantli
camel
serum
collect
unit
arab
emir
hemida
et
al
perera
et
al
reusken
et
al
meyer
et
al
merscov
neutral
antibodi
detect
speci
livestock
test
includ
chicken
goat
sheep
cattl
seroposit
among
camel
pass
everi
locat
even
hemida
et
al
perera
et
al
reusken
et
al
b
meyer
et
al
high
preval
neutral
antibodi
across
age
grade
suggest
pervas
earli
infect
camel
merscov
merscovlik
viru
recent
merscov
viru
detect
rtpcr
nose
swab
three
camel
qatar
camel
epidemiolog
link
two
human
case
merscov
viral
fragment
sequenc
camel
show
high
similar
sequenc
human
case
datum
provid
conclus
evid
dromedari
camel
form
part
merscov
outbreak
pictur
direct
transmiss
still
unclear
fig
transmiss
could
occur
camel
human
human
camel
concurr
third
sourc
human
camel
furthermor
detect
merscov
neutral
antibodi
dromedari
camel
region
report
human
case
egypt
canari
island
rais
question
extent
merscov
merscovlik
viru
circul
africa
arab
peninsula
minor
asia
reusken
et
al
movement
camel
africa
arabian
peninsula
common
could
contribut
spread
merscov
region
mukasamugerwa
perera
et
al
respect
role
humantohuman
zoonot
transmiss
current
merscov
outbreak
well
understood
fig
conclus
evid
humantohuman
transmiss
merscov
first
report
cluster
merscov
case
unit
kingdom
adult
male
travel
saudi
arabia
transmit
viru
two
famili
member
health
protect
agenc
overal
merscov
humantohuman
transmiss
chain
selflimit
irregular
half
secondari
merscov
case
origin
healthcar
set
largest
cluster
merscov
date
involv
patient
three
differ
healthcar
facil
eastern
provinc
saudi
arabia
highlight
potenti
nosocomi
transmiss
assiri
et
al
hand
earli
merscov
patient
transfer
qatar
specialist
lung
hospit
germani
given
intens
treatment
almost
month
hospit
learn
merscov
diagnosi
extens
contact
investig
serolog
analysi
potenti
expos
patient
reveal
secondari
infect
buchholz
et
al
screen
merscov
patient
contact
uncov
least
instanc
asymptomat
merscov
infect
healthcar
worker
contact
although
role
subclin
case
play
transmiss
infect
unclear
memish
et
al
merscov
research
group
transmiss
respiratori
virus
often
directli
associ
amount
viru
shed
dynam
merscov
shed
throughout
cours
diseas
well
character
high
viral
load
detect
bronchoalveolar
lavag
sampl
infect
patient
suggest
cough
exud
lower
respiratori
tract
could
import
mechan
merscov
humantohuman
transmiss
de
sousa
et
al
zoonot
sourc
merscov
continu
play
role
outbreak
epidemiolog
repeat
introduct
viru
human
popul
cotten
et
al
b
identifi
sporad
case
merscov
defin
occur
known
human
exposur
merscov
research
group
earli
cluster
primari
case
adult
male
suggest
activ
uniqu
adult
male
arabian
peninsula
may
expos
viru
sourc
penttinen
et
al
interestingli
rate
sever
diseas
death
higher
primari
merscov
patient
secondari
case
despit
similar
preval
comorbid
merscov
research
group
could
result
higher
dose
viru
exposur
among
primari
patient
epidemiolog
dynam
describ
basic
reproduct
number
r
merscov
uncertain
r
measur
number
secondari
case
gener
one
case
diseas
populationan
r
selflimit
within
popul
use
epidemiolog
inform
probabl
case
merscov
infect
two
differ
transmiss
scenario
use
estim
r
merscov
breban
et
al
one
scenario
model
larg
number
index
patient
per
cluster
gener
small
transmiss
tree
reflect
possibl
two
epidemiolog
link
case
could
expos
nonhuman
sourc
merscov
scenario
yield
r
yearli
merscov
introduct
rate
breban
et
al
second
scenario
use
lower
rate
introduct
higher
humantohuman
transmiss
predict
r
yearli
introduct
rate
breban
et
al
largescal
analysi
fullgenom
sequenc
merscov
identifi
multipl
zoonot
introduct
viru
distinct
genom
circul
geograph
space
provid
evid
multipl
zoonot
introduct
transmiss
dynam
agreement
lower
r
cotten
et
al
furthermor
comparison
r
predict
merscov
prepandem
sarscov
r
suggest
merscov
low
pandem
potenti
breban
et
al
anoth
transmiss
model
merscov
case
predict
similar
r
warn
absenc
control
measur
r
could
rang
allow
selfsustain
transmiss
cauchemez
et
al
base
extrapol
incid
diseas
travel
return
merscovsourc
countri
predict
mani
symptomat
case
merscov
may
occur
august
cauchemez
et
al
epidemiolog
studi
necessari
assess
preval
circul
merscov
infect
human
popul
pair
genom
merscov
consist
least
ten
polycistron
open
read
frame
orf
organ
follow
coronavirus
gener
master
van
boheemen
et
al
twothird
end
coronaviru
genom
compos
replicas
open
read
frame
master
merscov
orf
translat
two
polyprotein
one
requir
ribosom
frame
shift
eventu
cleav
put
nonstructur
protein
nsp
sawicki
et
al
van
boheemen
et
al
role
nsp
empir
determin
merscov
function
predict
base
conserv
domain
character
coronavirus
instanc
put
serv
rdrp
thought
function
proofread
exoribonucleas
exon
van
interestingli
coronavirus
rna
virus
known
use
specif
proofread
enzym
mainten
highfidel
viral
rna
replic
smith
et
al
downstream
two
larg
orf
least
nine
orf
encod
structur
proteinsspik
envelop
membran
nucleocapsidand
accessori
protein
translat
downstream
orf
occur
via
subgenom
mrna
salient
featur
order
coronavirus
belong
nidoviral
sawicki
et
al
grant
bind
viru
host
cell
cellular
receptor
play
import
role
determin
speci
tissu
tropism
coronavirus
thackray
holm
master
tusel
et
al
merscov
spike
protein
amino
acid
typei
transmembran
glycoprotein
present
trimer
surfac
envelop
viru
translat
spike
protein
cleav
two
domain
subunit
respons
receptor
bind
unit
mediat
membran
fusion
ohnuma
et
al
raj
et
al
spike
glycoprotein
bind
surfac
enzym
dipeptidyl
peptidas
also
known
typeii
transmembran
glycoprotein
catalyz
cleavag
ntermin
prolinecontain
dipeptid
aid
glucos
metabol
proteolyt
inactiv
incretin
engel
et
al
hiramatsu
et
al
lambeir
et
al
third
exopeptidas
found
act
receptor
coronavirus
block
enzymat
activ
affect
merscov
suscept
signific
enzym
receptor
coronavirus
thought
lie
widespread
express
endotheli
epitheli
tissu
rel
conserv
mammalian
speci
allow
merscov
bind
speci
divers
bat
human
raj
et
al
receptorbind
domain
rbd
merscov
region
spike
protein
attach
receptor
map
amino
acid
residu
region
spike
protein
chen
et
al
lu
et
al
mou
et
al
wang
et
al
cocrystal
merscov
spike
protein
reveal
interact
betapropel
blade
betastrand
merscov
rbd
also
known
receptorbind
motif
rbm
fig
lu
et
al
wang
et
al
rbd
spike
protein
induc
neutral
antibodi
make
import
target
develop
prophylact
therapeut
agnihothram
et
al
du
et
al
b
c
gierer
et
al
song
et
al
preliminari
investig
merscov
host
interact
innat
immun
respons
perform
vitro
ex
vivo
vivo
nonhuman
primat
model
merscov
shown
replic
vitro
human
bat
porcinederiv
cell
line
wherea
cow
hamster
murin
rat
canin
cell
line
suscept
chan
et
al
dijkman
et
al
kindler
et
al
raj
et
al
scobey
et
al
vitro
model
hold
predict
valu
merscov
suscept
vivo
complet
character
mechan
cellular
entri
necessari
understand
host
suscept
leow
instanc
speci
tropism
merscov
appear
restrict
variabl
cellular
receptor
merscov
unabl
replic
mice
hamster
ferretscommon
small
anim
modelsand
merscov
spike
glycoprotein
unabl
bind
ferretspecif
coleman
et
al
de
wit
et
al
raj
et
al
linear
organ
subunit
merscov
spike
glycoprotein
variabl
rbd
locat
amino
acid
residu
rbm
contain
critic
amino
acid
residu
bind
residu
b
crystal
structur
merscov
rbd
coupl
receptor
dipeptidyl
peptidas
iv
structur
divid
alphaand
betahydrolas
domain
betapropel
domain
betapropel
domain
pink
interact
rbm
region
light
blue
merscov
spike
protein
rbd
schemat
represent
merscov
spike
protein
rbd
structur
gener
use
chimera
protein
access
number
lu
et
al
josset
et
al
yet
consist
observ
sarscov
infect
merscov
infect
human
respiratori
cell
lead
pronounc
typei
ifn
respons
kopeckybromberg
et
al
kindler
et
al
zielecki
et
al
typei
ifn
play
key
role
viral
immun
pathogen
virus
often
evad
innat
immun
antagonist
protein
disrupt
ifn
reaction
garc
biron
randal
goodbourn
taylor
mossman
merscov
inhibit
typei
ifn
demonstr
structur
protein
accessori
protein
encod
orf
orf
orf
potent
inhibitor
orf
shown
inhibit
typei
ifn
activ
block
interact
rna
helicas
sensor
viral
doublestrand
rna
mechan
distinct
employ
sarscov
kopeckybromberg
et
al
niemey
et
al
yang
et
al
effici
merscov
replic
also
demonstr
noncili
bronchial
epithelium
alveolar
epitheli
cell
endotheli
cell
macrophag
human
ex
vivo
organ
cultur
chan
et
al
zhou
et
al
consist
result
obtain
human
respiratori
cell
line
merscov
infect
ex
vivo
lead
strong
typei
ifn
respons
cultur
chan
et
al
zhou
et
al
combin
vitro
ex
vivo
data
suggest
merscov
activ
interact
evad
innat
immun
recognit
pathway
host
kindler
et
al
ex
vivo
data
support
result
viral
dissemin
patholog
cellular
tropism
establish
rhesu
macaqu
model
gene
express
analysi
experiment
infect
rhesu
macaqu
show
differenti
express
gene
infect
lung
tissu
associ
antivir
immun
inflamm
chemotaxi
includ
chemokin
cxc
ligand
matrix
metalloproteinas
expect
typei
ifn
activ
de
wit
et
al
chemokin
strong
recruit
neutrophil
granulocyt
induc
macaqu
perhap
explain
increas
number
neutrophil
record
blood
infect
macaqu
human
patient
zaki
et
al
assiri
et
al
gueri
et
al
de
wit
et
al
mathemat
transmiss
model
highlight
two
import
way
merscov
control
reduc
rate
merscov
introduct
human
popul
break
chain
humantohuman
transmiss
reduct
rate
merscov
introduct
human
popul
requir
comprehens
understand
nonhuman
sourc
merscov
spatial
tempor
dynam
merscov
circul
sourc
hand
interrupt
humantohuman
transmiss
cycl
merscov
call
understand
paramet
involv
transmiss
viru
shed
stabil
rout
transmiss
although
rout
transmiss
merscov
well
understood
spread
merscov
peopl
close
contact
set
suggest
direct
contact
fomit
transmiss
rout
like
involv
state
local
merscov
infect
lower
respiratori
tract
implic
cough
exud
import
sourc
viru
shed
addit
environment
stabil
merscov
provid
inform
potenti
fomit
transmiss
low
temperatur
humid
merscov
sarscov
virion
retain
viabil
smooth
surfac
much
longer
mani
respiratori
virus
includ
influenza
viru
sizun
et
al
chan
et
al
van
doremalen
et
al
thu
temperaturecontrol
set
hospit
may
particular
risk
fomit
transmiss
merscov
perform
highrisk
patient
care
procedur
intub
manual
ventil
along
inconsist
use
surgic
mask
associ
nosocomi
transmiss
sarscov
healthcar
worker
ofneragostini
et
al
nishiyama
et
al
healthcar
worker
grow
cohort
merscov
case
rout
exposur
may
similar
virus
merscov
outbreak
character
hospitalbas
superspread
event
defin
epidemiolog
sarscov
lipsitch
et
al
infect
sarscov
viral
load
upper
respiratori
tract
secret
remain
low
first
day
ill
peak
nasopharyng
aspir
day
onset
symptom
peiri
et
al
cheng
et
al
thu
sarscov
transmiss
could
prevent
gener
popul
basic
public
health
infect
control
measur
isol
patient
negativepressur
room
activ
surveil
quarantin
contact
provis
educ
protect
equip
healthcar
worker
twu
et
al
svoboda
et
al
estim
serial
interv
merscov
infect
largest
cluster
merscov
date
case
hospit
settingar
slightli
shorter
sarscov
median
vs
day
suggest
transmiss
may
occur
earlier
cours
ill
assiri
et
al
effect
implement
public
health
measur
current
merscov
outbreak
must
integr
knowledg
shed
dynam
exposur
mechan
viru
viabil
antivir
treatment
specif
human
coronavirus
develop
shortliv
sarscov
outbreak
support
treatment
regimen
optim
stockman
et
al
cheng
et
al
commerci
avail
drug
typei
ifn
lopinavir
high
concentr
ribavirin
shown
inhibit
cytopath
effect
sarscov
vitro
studi
synergist
antivir
effect
describ
typei
ifn
ribavirin
chen
et
al
tan
et
al
birgit
et
al
drug
use
vari
extent
sarscov
patient
often
combin
corticosteroid
stockman
et
al
cheng
et
al
ribavirin
structur
analog
guanosin
broadspectrum
mutagen
effect
virus
despit
frequent
use
sarscov
patient
ribavirin
shown
effect
patient
advers
effect
hemolyt
anemia
common
stockman
et
al
cheng
et
al
typei
ifn
regimen
sarscov
patient
sometim
use
part
multidrug
regimen
one
studi
sarscov
patient
report
rapid
improv
radiograph
lung
patholog
better
oxygen
patient
treat
loutfi
et
al
stockman
et
al
cheng
et
al
specul
immunopatholog
rather
uncontrol
viral
replic
contribut
lung
deterior
advanc
sarscov
infect
favor
widespread
use
corticosteroid
treatment
nichol
et
al
peiri
et
al
hui
sung
cheng
et
al
retrospect
analysi
sarscov
patient
show
benefit
corticosteroid
administr
except
critic
case
analyz
alon
deathrel
variabl
adjust
among
critic
patient
corticosteroid
therapi
significantli
reduc
case
fatal
chen
similarli
corticosteroid
use
merscov
patient
sever
diseas
guberina
et
al
memish
et
al
omrani
et
al
one
previous
healthi
merscov
patient
suffer
ard
multidrugresist
pseudomona
aeruginosa
suspect
concomit
allerg
bronchopulmonari
aspergillosi
improv
rapidli
treat
corticosteroid
prednisolon
guberina
et
al
efficaci
corticosteroid
treatment
merscov
patient
ard
report
therapi
use
sarscov
outbreak
shape
investig
treatment
regimen
mer
cov
merscov
show
greater
sensit
sarscov
antivir
effect
typei
typeiii
ifn
vitro
ex
vivo
kindler
et
al
wild
et
al
zielecki
et
al
greater
sensit
could
explain
mechanist
differ
ifn
antagonist
accessori
protein
virus
instanc
merscov
lack
homologu
sarscov
protein
block
effect
ifn
ultim
transcript
activ
downstream
antivir
gene
wild
et
al
comparison
five
differ
ifn
shown
ifnb
potent
inhibitor
merscov
hart
et
al
although
high
concentr
ribavirin
effect
vitro
one
studi
anoth
studi
found
inhibitori
effect
ribavirin
dose
translat
current
drug
regiment
human
hart
et
al
ribavirin
use
combin
merscov
howev
effect
concentr
ec
drug
combin
much
lower
individu
drug
addit
effect
decreas
drug
requir
concentr
potenti
achiev
human
interestingli
ribavirin
significantli
effect
exon
activ
coronavirus
knock
smith
et
al
data
indic
knockout
virus
ribavirin
greater
abil
inhibit
viral
rna
synthesi
inosin
monophosph
dehydrogenas
impdh
enzym
necessari
de
novo
synthesi
guanin
nucleotid
would
explain
rel
high
ribavirin
dose
need
achiev
inhibit
viral
replic
merscov
smith
et
al
studi
identifi
compound
inhibit
merscov
mycophenol
acid
demonstr
particularli
high
efficaci
merscov
ec
lm
chan
et
al
b
c
mycophenol
acid
approv
drug
like
ribavirin
act
inhibit
impdh
typic
use
immunosuppress
tissu
transplant
antivir
activ
attribut
inhibit
viral
rna
replic
diamond
et
al
preliminari
vitro
comparison
suggest
mycophenol
acid
potent
inhibitor
merscov
ribavirin
chan
et
al
hart
et
al
effect
plasma
drug
level
may
better
achiev
intraven
dose
mycophenol
acid
ribavirin
chan
et
al
assumpt
vivo
use
drug
effect
vitro
need
made
care
mycophenol
acid
instanc
potent
inhibitor
b
lymphocyt
dendrit
cell
matur
effect
suppress
antigen
present
immunoglobulin
product
villarroel
et
al
wellcharacter
anim
model
advers
immunomodulatori
effect
drug
may
outweigh
reduct
merscov
virul
attempt
establish
small
anim
model
merscov
syrian
hamster
mice
ferret
unsuccess
coleman
et
al
raj
et
al
b
de
wit
et
al
howev
experiment
infect
studi
rhesu
macaqu
show
anim
speci
suscept
merscov
rhesu
macaqu
merscov
caus
lower
respiratori
tract
infect
reminisc
mild
moder
human
case
clinic
sign
merscovinfect
macaqu
includ
cough
increas
respir
rate
lung
sampl
show
lesion
characterist
mild
mark
pneumonia
de
wit
et
al
viru
detect
throughout
respiratori
tract
mediastin
lymph
node
viral
load
higher
earlier
infect
primari
site
viru
replic
typei
typeii
pneumocyt
main
compon
alveolar
architectur
replic
merscov
deep
macaqu
lower
respiratori
tract
may
explain
low
potenti
transmiss
merscov
despit
renal
failur
human
patient
viru
absent
kidney
tissu
macaqu
recent
character
merscov
rhesu
macaqu
report
transient
fever
infect
monkey
demonstr
merscovspecif
antibodi
respons
macaqu
start
day
postinfect
yao
et
al
rhesu
macaqu
model
merscov
infect
vivo
model
establish
date
develop
small
anim
model
essenti
conduct
widespread
research
pathogenesi
prophylact
therapeut
countermeasur
antivir
immun
modulatori
compound
shown
effect
merscov
vitro
one
treatment
option
examin
vivo
efficaci
combin
ribavirin
treatment
regimen
test
merscovinfect
rhesu
macaqu
dose
design
achiev
serum
concentr
ec
valu
determin
vitro
treat
anim
show
clinic
sign
hematolog
chang
develop
untreat
anim
breath
difficulti
decreas
oxygen
satur
level
increas
neutrophil
count
gross
patholog
lung
treat
anim
normal
untreat
anim
display
visibl
lesion
histopatholog
reveal
mild
sign
bronchointerstiti
pneumonia
treat
anim
abund
alveolar
edema
sever
lesion
seen
untreat
anim
merscov
viral
load
lung
sampl
log
lower
treat
anim
compar
untreat
anim
furthermor
lungspecif
host
respons
occur
untreat
macaqu
treat
anim
increas
level
cytokin
chemokin
ifni
reduc
express
inflammatori
gene
observ
lung
treat
anim
signific
improv
clinic
score
treat
anim
despit
rel
similar
viral
load
group
suggest
immunopatholog
may
factor
sever
merscov
infect
howev
rhesu
macaqu
model
recapitul
mild
moder
diseas
human
effect
drug
merscovinduc
ard
unclear
time
also
critic
efficaci
treatment
patient
begin
treatment
quit
ill
wherea
drug
regimen
macaqu
began
h
postinocul
translat
drug
regimen
laboratori
clinic
must
address
discrep
year
sinc
sarscov
outbreak
attempt
made
prepar
reemerg
establish
vaccin
advent
merscov
heighten
need
effect
coronaviru
vaccin
inactiv
virus
liveattenu
virus
dna
vaccin
viruslik
particl
viral
vectorbas
vaccin
shown
produc
neutral
antibodi
sarscov
chen
et
al
zhao
et
al
graham
et
al
tseng
et
al
unfortun
sarscov
caus
pulmonari
immunopatholog
upon
challeng
vaccin
anim
model
presum
induc
immun
respons
skew
toward
helper
h
cell
respons
tseng
et
al
inactiv
viru
vaccin
particularli
prone
induc
type
h
hypersensit
immunopatholog
upon
challeng
observ
sarscovbas
viral
vector
vaccin
deme
et
al
viruslik
particl
vaccin
tseng
et
al
dna
vaccin
zhao
et
al
investig
antigen
serolog
relationship
merscov
coronavirus
confirm
neutral
antibodi
target
spike
protein
merscov
specif
merscov
n
protein
induc
antibodi
crossreact
within
coronaviru
subgroup
agnihothram
et
al
spike
protein
especi
rbd
consid
key
compon
coronaviru
vaccin
design
du
et
al
du
et
al
replicationdefect
vaccinia
virusbas
vaccin
express
fulllength
spike
protein
merscov
shown
produc
high
level
neutral
antibodi
mice
viru
challeng
appli
mous
model
song
et
al
vaccin
recombin
protein
contain
truncat
rbd
spike
protein
amino
acid
fc
human
igg
also
induc
high
titer
neutral
antibodi
truncat
rbd
elicit
higher
level
neutral
antibodi
vaccin
recombin
protein
contain
larger
fragment
spike
protein
amino
acid
author
suggest
nonneutr
epitop
within
region
polypeptid
may
compet
neutral
epitop
destabil
format
rbd
du
et
al
maxim
protect
neutral
antibodi
across
merscov
strain
natur
variat
merscov
spike
protein
need
character
consid
design
vaccin
graham
et
al
liveattenu
virus
anoth
approach
merscov
vaccin
develop
merscov
mutant
lack
structur
e
protein
shown
replicationcompet
propagationdefect
almaz
et
al
develop
safe
effect
merscov
vaccin
must
potenti
overcom
challeng
aros
sarscov
vivo
test
vaccin
perform
date
remain
therefor
unclear
whether
challeng
merscov
would
illicit
pulmonari
immunopatholog
upon
challeng
creativ
approach
use
adjuv
promot
h
cell
respons
need
pursu
potenti
vaccin
must
rigor
evalu
anim
model
graham
et
al
year
sinc
identif
merscov
spread
across
arab
peninsula
transport
unit
kingdom
franc
germani
itali
tunisia
spain
bermingham
et
al
buchholz
et
al
gulland
b
health
protect
agenc
hijawi
et
al
maill
et
al
memish
et
al
puzelli
et
al
initi
detect
merscov
follow
rapid
develop
merscov
molecular
serolog
diagnost
corman
et
al
b
emerg
merscov
remind
infecti
diseas
commun
emerg
sarscov
call
immedi
public
health
prepared
respons
research
effort
larg
focus
epidemiolog
outbreak
identif
put
natur
intermedi
reservoir
potenti
therapeut
controversi
surround
identif
share
merscov
isolatesth
initi
isol
share
without
consent
saudi
arabian
govern
materi
transfer
agreement
mta
isol
said
unnecessarili
restrict
butler
mta
sever
purpos
defin
materi
transfer
use
materi
purpos
transfer
also
protect
intellectu
properti
right
parti
defin
ownership
origin
materi
invent
result
use
materi
lastli
design
liabil
parti
ensur
receiv
parti
use
materi
safe
way
instanc
proper
biosafeti
level
controversi
surround
initi
detect
merscov
highlight
import
creat
intern
framework
rapid
global
share
viru
strain
biolog
materi
outbreak
similar
controversi
ownership
arisen
avian
influenza
fidler
avian
flu
viru
merscov
case
strongli
point
need
prenegoti
transfer
agreement
also
standard
best
practic
guidelin
highli
virul
emerg
diseas
materi
expedit
share
materi
data
paramount
import
despit
mani
advanc
understand
merscov
outbreak
major
question
remain
epidemiolog
merscov
still
poorli
understood
although
dromedari
camel
implic
like
intermedi
reservoir
detail
genet
variat
merscov
virus
circul
camel
human
necessari
identifi
camel
definit
sourc
human
merscov
infect
widespread
distribut
dromedari
camel
across
africa
arab
peninsula
southwest
asia
highlight
potenti
facilit
outbreak
spread
fig
inform
spatial
tempor
pattern
merscov
circul
speci
need
zoonot
introduct
continu
play
role
epidemiolog
merscov
human
cotten
et
al
elucid
mechan
zoonot
transmiss
essenti
intervent
strategi
focu
control
event
clinic
understand
merscov
infect
base
limit
report
albarrak
et
al
bermingham
et
al
assiri
et
al
drosten
et
al
gueri
et
al
memish
et
al
omrani
et
al
particular
interest
effect
comorbid
merscov
pathogenesi
patient
outcom
preliminari
evid
show
direct
relat
underli
comorbid
diseas
sever
observ
primari
case
sever
fig
geograph
distribut
dromedari
camel
global
distribut
dromedari
camel
indic
yellow
shade
mukasamugerwa
secondari
case
even
control
underli
condit
might
suggest
primari
case
expos
higher
viru
dose
secondari
case
merscov
research
group
could
also
indic
merscov
readili
transmiss
intermedi
reservoir
human
humantohuman
milder
merscov
case
would
less
like
effici
transmit
merscov
humantohuman
transmiss
could
increas
merscov
becom
better
adapt
human
prolong
merscov
replic
immunecompromis
patient
could
increas
opportun
viru
acquir
mutat
enabl
effici
transmiss
develop
test
merscov
therapeut
current
hinder
absenc
small
anim
model
addit
phase
iiii
clinic
trial
need
conduct
experiment
vaccin
treatment
option
avail
human
accordingli
research
focus
alreadyapprov
drug
treatment
merscov
result
faster
implement
wider
avail
therapeut
clinic
increas
emerg
infecti
diseas
event
last
decad
made
appar
complet
understand
ecolog
biolog
polit
economi
infecti
diseas
emerg
necessari
global
climat
chang
habitat
alter
wildlif
encroach
like
contribut
novel
interact
pathogen
host
adequ
prepar
futur
infecti
diseas
outbreak
requir
strong
intern
relationship
research
monitor
surveil
public
health
respons
face
emerg
sarscov
avian
influenza
develop
intern
health
regul
coordin
global
respons
emerg
health
threat
structur
merscov
respons
accord
regul
form
emerg
committe
merscov
creat
case
definit
infect
provid
frequent
updat
merscov
outbreak
ihr
global
alert
respons
function
program
monitor
emerg
diseas
promedmail
commun
first
report
merscov
infect
human
also
continu
provid
global
health
research
commun
updat
epidemiolog
report
scientif
find
capac
build
knowledg
transfer
train
futur
gener
scientist
key
factor
form
multidisciplinari
prepared
futur
infecti
diseas
outbreak
regard
special
attent
given
prevent
control
emerg
infecti
diseas
develop
world
origin
major
infecti
diseas
outbreak
